Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin P Rock

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Medicine|November 14, 2023
Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapyJerome H Goldschmidt, Lin-Na Chou, Philip K Chan, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
Frontiers in Immunology|January 23, 2023
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disordersHillard M Lazarus, Katherine Pitts, Tisha Wang, et al.
American Heart Journal|April 21, 2009
Assessing proarrhythmic potential of drugs when optimal studies are infeasibleEdwin P Rock, John Finkle, Howard J Fingert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinomaVicki L Goodman, Edwin P Rock, Ramzi Dagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Patient-reported outcomes assessment in cancer trials: taking stock, moving forwardJoseph Lipscomb, Bryce B Reeve, Steven B Clauser, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
JAMA Oncology|January 22, 2021
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Medicine|November 14, 2023
Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapyJerome H Goldschmidt, Lin-Na Chou, Philip K Chan, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
Frontiers in Immunology|January 23, 2023
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disordersHillard M Lazarus, Katherine Pitts, Tisha Wang, et al.
American Heart Journal|April 21, 2009
Assessing proarrhythmic potential of drugs when optimal studies are infeasibleEdwin P Rock, John Finkle, Howard J Fingert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinomaVicki L Goodman, Edwin P Rock, Ramzi Dagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2007
Patient-reported outcomes assessment in cancer trials: taking stock, moving forwardJoseph Lipscomb, Bryce B Reeve, Steven B Clauser, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
JAMA Oncology|January 22, 2021
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.
Pageof 2